Replies to post #888 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Yes, MSS CRC is dominated by myeloid cells and CAFs, so it may need additional 'priming' strategies* (before the CAR-T infusion).

* Low-dose radiotherapy, low-dose chemo (5-FU is another that could be used as it has been shown to kill MDSCs), COX-2 inhibitor and low-dose panobinostat.